Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials

JAMA

Volumn 279, Issue 4, 1998, Pages 281-286

  Loannidis, John P A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MODEL; MULTICENTER STUDY; PEER REVIEW; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; STATISTICAL ANALYSIS; SURVIVAL;

EID: 0032573850     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.4.281     Document Type: Article

References (29)

1. Easterbrook P, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337:867-872.
2. Dickersin K, Min YI. NIH clinical trials and publication bias. Online J Cure Clin Trials. April 28, 1993;doc 50.
3. Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA. 1990;263: 1385-1389.
4. Dickersin K, Min Y-I. Publication bias: the problem that won't go away. Ann N Y Acad Sci. 1993; 703:135-148.
5. Dickersin K, Min Y-I, Meinert CL. Factors influencing publication of research results: follow-up of applications submitted to two institutional review boards. JAMA 1992;267:374-378.
6. Hetherington J, Dickersin K, Chalmers I, Meinert C. Retrospective and prospective identification of unpublished controlled trials: lessons from a survey of obstetricians and pediatricians. Pediatrics. 1989;84: 374-380.
7. Scherer RW, Dickersin K, Langenberg P. Full publication of results initially presented as abstracts: a meta-analysis. JAMA 1994;272:158-162.
8. Simes RJ. Publication bias: the case for an international registry of clinical trials. J Clin Oncol. 1986; 4:1529-1541.
9. Ioannidis JPA, Cappelleri JC, Schmid CH, Lau J. Impact of epidemic and individual heterogeneity on the population distribution of disease progression rates: an example from populations of trials of human immunodeficiency virus infection. Am J Epidemiol. 1996;144:1074-1085.
10. Koren G. Bias against negative studies in newspaper reports of medical research. JAMA. 1991;266:1824-1826.
11. Koren G, Graham K, Shear H, Einarson T. Bias against the null hypothesis: the reproductive hazards of cocaine. Lancet, 1989;2:1440-1442.
12. Cooper DA, Gatell JM, Kroon SA, et al. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. N Engl J Med. 1993;329:297-303.
13. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med. 1990;322:941-941.
14. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet. 1994;343:871-881.
15. Youle MS, Gazzard BG, Johnson MA, et al. Effects of high-dose oral acyclovir on herpesvirus disease and survival in patients with advanced HIV disease: a double-blind, placebo controlled study. AIDS. 1994;8:641-649.
16. Hersh EM, Brewton G, Abrams D, et al. Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS: a randomised, double-blind, placebo-controlled multicenter study. JAMA. 1991;265:1538-1544.
17. The HIV87 Study Group. Multicenter, randomized, placebo-controlled study of ditiocarb (Imuthiol) in human immunodeficiency virus-infected asymptomatic and minimally symptomatic patients. AIDS Res Hum Retrovituses. 1993;9:83-89.
18. Spector SA, McKinley GF, Lalezari JP, et al. Oral ganciclovir for the prevention of cytomegalo-virus disease in persons with AIDS. N Engl J Med. 1996;334:1491-1497.
19. Ioannidis JPA, Cappelleri JC, Sacks HS, Lau J. The relationship between study design, results and reporting of randomized clinical trials of HIV infection. Control Clin Trials. 1997;18:431-444.
20. Ioannidis JPA, Cappelleri JC, Lau J, et al. Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness: a meta-analysis. Ann Intern Med. 1995;122:856-866.
21. DeMets DL, Fleming TR, Whitley RJ, et al. The Data and Safety Monitoring Board and acquired immune deficiency syndrome trials. Control Clin Trials. 1995;16:408-421.
22. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549-556.
23. Blumenthal D, Campbell EG, Anderson MS, Causino N, Louis KS. Withholding research results in academic life sciences: evidence from a national survey of faculty. JAMA 1997;277:1224-1228.
24. Rennie D. Thyroid storm [published correction appears in JAMA. 1997;277;1762]. JAMA. 1997;277: 1238-1243.
25. Cappelleri JC, Ioannidis JPA, Schmid CH, et al. Large trials vs meta-analysis of smaller trials: how do their results compare? JAMA. 1996;276:1332-1338.
26. Ioannidis JP, Lau J. The impact of high risk patients on the results of clinical trials. J Clin Epidemiol. 1997;50:1089-1098.
27. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med. 1992;327:248-254.
28. McIntosh M. The population risk as an explanatory variable in research synthesis of clinical trials. Stat Med. 1996;15:1713-1728.
29. Ioannidis JP, Lau J. On meta-analyses of meta-analyses. Lancet. 1996;248:756.